Jürgen Floege - Publications, H-index & Citations

Sustainability and depth of UPCR reduction in patients with primary IgAN treated with nefecon: a secondary analysis of the Phase 3 NefIgArd trial nefecon治疗的原发性IgAN患者中UPCR降低的持续性与深度：NefIgArd 3期试验的二次分析

IF5.6

2025-10-01

OAAI

Barratt, Jonathan; Lafayette, Richard; Reich, Heather; Kristensen, Jens; Jones, Russell; Floege, Jurgen; Tesar, Vladimir; Trimarchi, Hernan; Zhang, Hong; Rovin, Brad

Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study Nefecon在IgAN患者中提供肾脏获益，且与诊断时间无关：NefIgArd研究的一项亚组分析

IF5.6

2025-10-01

OAAI

Barratt, Jonathan; Reich, Heather; Kristensen, Jens; Jones, Russell; Floege, Jurgen; Tesar, Vladimir; Trimarchi, Hernan; Zhang, Hong; Rovin, Brad; Lafayette, Richard

Origin 3 study design: a global, randomized, controlled, Phase 3 study of atacicept in IgA nephropathy Origin 3研究设计：一项关于atacicept在IgA肾病中的全球性、随机化、对照性III期研究

IF5.6

2025-10-01

OAAI

Lafayette, Richard; Barratt, Jonathan; Reich, Heather; Kristensen, Jens; Jones, Russell; Floege, Jurgen; Tesar, Vladimir; Trimarchi, Hernan; Zhang, Hong; Rovin, Brad

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)KDIGO 2025年免疫球蛋白A肾病（IgAN）和免疫球蛋白A血管炎（IgAV）临床实践指南

IF5.6

2025-10-01

PREAI

Lafayette, Richard; Maes, Bart; Brenner, Robert; Khawaja, Zeeshan; Floege, Jurgen; Jha, Vivekanand; Tesar, Vladimir; Zhang, Hong; Barbour, Sean; Suzuki, Hitoshi; Trimarchi, Hernan; Barratt, Jonathan

Kidney International

IF12.6

2025-09-18

OAAI

Brad H. Rovin; Jonathan Barratt; H. Terence Cook; Irene L. Noronha; Heather N. Reich; Yusuke Suzuki; Sydney C.W. Tang; Hernán Trimarch; Jürgen Floege

KDIGO 2025 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF NEPHROTIC SYNDROME IN CHILDREN KDIGO 2025 儿童肾病综合征管理临床实践指南

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children KDIGO 2025年儿童肾病综合征管理临床实践指南执行摘要

IF12.6

2025-05-01

OAAI

Floege, Jurgen; Gibson, Keisha L.; Liew, Adrian; Rovin, Brad H.; Radhakrishnan, Jai; Tonelli, Marcello A.

Vitamin K preserves gamma-glutamyl carboxylase activity against carbamylations in uremia: Implications for vascular calcification and adjunct therapies 维生素K通过对抗尿毒症中的氨甲酰化作用来保护γ-谷氨酰羧化酶的活性：对血管钙化和辅助治疗的启示

IF12.6

2025-05-01

OAAI

Floege, Jurgen; Gibson, Keisha L.; Liew, Adrian; Radhakrishnan, Jai; Balk, Ethan M.; Gordon, Craig E.; Adam, Gaelen; Earley, Amy; Rovin, Brad H.

ACTA PHYSIOLOGICA

IF5.6

2025-04-09

OAAI

Kaesler, N; Kaushik, S; Frisch, J; Ziegler, S; Grommes, J; Gombert, A; Roma, LP; Kuppe, C; Jankowski, J; Floege, J; de la Puente-Secades, S; Kramann, R; Jankowski, V

The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency

Therapy of IgA nephropathy: time for a paradigm change

IF4.6

2025-04-01

OAAI

Buisker, Jocelyn; Behr, Sigrid; Kubesch, Nadine Janet; Turkson, Moise E.; Maes, Bart; Kollins, Dmitrij; Webb, Nicholas J. A.; Floege, Jurgen

FRONTIERS IN MEDICINE

IF3

2024-08-15

OAAI

Barratt, Jonathan; Lafayette, Richard A.; Floege, Juergen

Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a CKJ controversy

Long-term outcomes of patients with IgA nephropathy in the German CKD cohort 德国CKD队列中IgA肾病患者的长期预后

IF4.6

2024-08-12

OAAI

Caravaca-Fontan, Fernando; del Vecchio, Lucia; Praga, Manuel; Floege, Juergen; Zoccali, Carmine

The time is now: CKJ adopts new policies for patient representation and for more sex-inclusive research

IF4.6

2024-07-22

OAAI

Stamellou, Eleni; Nadal, Jennifer; Hendry, Bruce; Mercer, Alex; Seikrit, Claudia; Bechtel-walz, Wibke; Schmid, Matthias; Moeller, Marcus J.; Schiffer, Mario; Eckardt, Kai-uwe; Kramann, Rafael; Floege, Juergen

Physical exercise in haemodialysis patients: which type of exercise is more convenient?

IF4.6

2024-06-27

OAAI

Stevens, Kate, I; Woywodt, Alexander; Floege, Juergen

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

IF4.6

2024-06-10

OAAI

Halle, Martin; Manfredini, Fabio; Floege, Jurgen; Zoccali, Carmine

Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort 德国慢性肾脏疾病队列中FSGS成人的长期结果

IF12.6

2024-06-01

OAAI

Lafayette, Richard; Barbour, Sean; Israni, Rubeen; Wei, Xuelian; Eren, Necmi; Floege, Juergen; Jha, Vivekanand; Kim, Sung Gyun; Maes, Bart; Phoon, Richard K. S.; Singh, Harmeet; Tesar, Vladimir; Lin, Celia J. F.; Barratt, Jonathan

Moderator's view: after SGLT2i and MRA antagonists, where do we go?

IF4.6

2024-04-27

OAAI

Stamellou, Eleni; Nadal, Jennifer; Hendry, Bruce; Mercer, Alex; Bechtel-Walz, Wibke; Schiffer, Mario; Eckardt, Kai-Uwe; Kramann, Rafael; Moeller, Marcus J.; Floege, Juergen

A new alternative: inhibiting complement activation in patients with IgA nephropathy

IF4.6

2024-01-31

OAAI

Zoccali, Carmine; Floege, Jurgen